Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 02 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Dec 2018.
- 02 Sep 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.
- 09 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.